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Abstract
The aim of the present study was to focus on the effects of Vitamin D3 (VD3) 
supplementation (5.0 mg/kg, s.c.) on the NF-kB/p65, 17β-estradiol (17β-E2)/
VD3 receptors expression in the hippocampus in the long-term ovariectomized 
(OVX) rats treated with low dose of 17β-E2 (0.5 μg/rat, s.c.) submitted for the 
chronic unpredictable mild stress (CUMS) for 28 days. Sucrose preference (SPT), 
forced swimming (FST), and open-field (OFT) tests were conducted to estimate 
the anhedonia-/depression-like states. NF-kB/p65, 17β-E2/VD3 receptors levels in 
the hippocampus were evaluated by ELISA and Western blot assays. The findings 
demonstrated that VD3 at high dose (5.0 mg/kg, s.c.) in a combination with low 
dose of 17β-E2 decreased anhedonia in the SPT and depression-like behavior in the 
FST of the long-term OVX rats submitted to CUMS. VD3 (5.0 mg/kg) resulted in 
significant decreased levels of hippocampal NF-kB/p65 protein expression, as well 
as to the normalization of hippocampal 17β-E2/VD3 receptors levels in long-term 
OVX rats treated with 17β-E2 exposed to CUMS. In conclusion, VD3 (5.0 mg/kg, 
s.c.) in a combination with low dose of 17β-E2 had a synergic antianhedonic- and 
antidepressant-like effects in the adult female rats following long-term ovariectomy 
submitted to CUMS.
Keywords: vitamin D3, long-term ovariectomy, chronic unpredictable mild stress, 
NF-kB/p65, 17β-estradiol receptor, vitamin D3 receptors
1. Introduction
The menopausal transition is often associated with a multiplicity of manifesta-
tions, the most standard being neuropsychiatric [1, 2]. The role of ovarian hormones 
in affect-related disorders is of great interest for women transitioning through 
menopause [2, 3]. Mood disorders during menopause could partly be explained due 
to a loss of estrogen is known to have neuroprotective effects on brain [3]. Numerous 
experimental and clinical studies have documented that estrogen deficiency during 
menopause increases the susceptibility to mood disturbances, including anxiety 
[4–6]. There has been a discussion that menopausal hormonal therapy (MHT) may 
improve the symptoms of affective-related disorders or decrease the risk of develop-
ing these, yet some uncertainty still exist around this topic because as research has 
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also found that MHT does not entirely stop the development of affective-related 
symptoms [7].
Females going through menopause are at higher risk of developing Vitamin D 
(VD) deficiency due to a VD poor diet, restricted outdoor activity resulting in less 
sun exposure as well as a decreased capacity to produce enough calcitriol as a result 
of an age related decline in hydroxylation by the kidneys [8]. Our previous experi-
mental work has confirmed that hormonal profile in ovariectomized (OVX) female 
rodents is also characterized by VD deficiency or insufficiency [9, 10]. Traditional 
methods of affective-related disorders therapy, which also include antidepressants/
anxiolytics, are unfortunately of limited effectiveness [11]. Nutrient imbalance, 
especially VD3 deficiency, is considered as one of the critical causes, enabling the 
pathophysiological mechanisms for development of psychiatric disorders [12]. In 
the pathophysiological mechanisms of mood disorders, many trigger factors play a 
role, and it is argued that one of them could be a deficiency in VD3 [12].
VD3 deficiency has been proven to impact on the pathogenesis of various 
diseases, for example, autoimmune diseases, cardiovascular diseases, infections, 
osteoporosis, obesity, diabetes, and certain types of cancers [13–15]. A correlation 
between very low VD3 levels and numerous neuropsychiatric diseases and a correla-
tion between an impact of VD3 levels and normal brain functioning have also been 
found in recent studies [14–16]. VD receptors (VDRs) have been found present in 
the central nervous system [17], in the brain structures involved in processes of 
mood regulation (cingulate cortex, hippocampus, thalamus, and hypothalamus) 
[18]. In this line, it can be assumed that VD3 likely has humoral or neurohumoral 
activities in these brain structures. VD3 involves in the neurogenesis, neuroplas-
ticity, neuroprotection, and neuroimmunomodulation [19–21]. This fact creates 
a neurobiological basis to propose the involvement of VD in the mechanisms of 
neuropsychiatric disorders [22–26].
The neuroinflammation in the central nervous system is supposed to be one of 
the main trigger factors for the development of affective-related disorders [27, 28]. 
Taking this assumption into account, mood disturbances established in menopausal 
women might result from complex alterations in estradiol and VD3 levels, as well as 
neuroinflammation.
Nowadays, nuclear factor-kappa B (NF-κB) is postulated as the proinflamma-
tory transcription factor that controls proinflammatory cytokines expression and 
is involved in the mechanisms of many inflammatory and neuroinflammatory dis-
eases [29, 30]. NF-κB is triggered by stress and might mediate cellular responses to 
stressful life events, thereby critically involved in development of affective-related 
disorders [31–33]. The enhancement of NF-κB might induce the elevated produc-
tion of proinflammatory cytokines and diminished neurohormonal stress feedback 
[34]. Furthermore, NF-κB pathway is involved in antidepressant action of different 
psychotropic drugs that used for treatment of mood disorders [35]. Clinical studies 
using patients with mood disorders have shown that NF-κB levels are increased 
in the serum of such patients [35–37]. Using genetic and environmental model of 
depression, it was shown that the antidepressant effect of such pharmacological 
treatments was dependent on NF-κB-p65 acetylation [36, 37].
The hippocampus is one of the key structures of the brain, which plays a role in 
affective-related disorders [38]. Both estrogen and VD3 have been associated with 
the successful functioning of the hippocampus [1, 21, 25]. Basic and clinical studies 
have suggested that alterations in NF-kB/p65 signaling and in 17β-E2/VD3 receptors 
expression in the hippocampus, as well changes of serum estradiol/VD contents are 
very often registered at affective-related disorders [1, 23, 39]. Animal studies have 
documented that the impaired behavioral profile in OVX rats is correlated with 
increased NF-kB/p65 levels in the brain [40, 41].
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Recently, we found that VD3 (5.0 mg/kg, s.c.) reduced anhedonia and depres-
sion-like behavior of long-term adult ovariectomized (OVX) rats exposed to the 
chronic unpredictable mild stress (CUMS) in the sucrose preference (SPT) and 
forced swimming (FST), respectively [42]. However, the therapeutic effects of VD3 
in a combination with low dose of 17β-E2 in female rats with long-lasting decline 
of estrogens exposed to CUMS remain unknown. Furthermore, it is still unclear 
whether the antidepressant-like action of VD3 plus 17β-E2 application implicates 
NF-kB/p65 signaling pathway and modifications of 17β-E2/VD3 receptors expres-
sion in the hippocampus of long-term OVX adult rats with CUMS.
The current investigation was performed to clarify the antidepressant-like effect 
of a combination with VD3 plus low dose of 17β-E2 on a rat model of CUMS in the 
female rats with long-lasting decline of estrogens. Similar to previously published 
work [43], we used long-lasting estrogen deficiency caused by a post-ovariectomy 
period of 3 months. This animal model is widely utilized in preclinical behavioral 
research producing a menopausal-like state in women [44]. Such behavioral tests as 
sucrose preference (SPT), forced swimming (FST), and open-field (OFT) were car-
ried out to examine the depression-like behavior. NF-kB/p65, 17β-E2/VD3 receptors 
levels in the hippocampus and serum estradiol and VD concentrations were deter-
mined to assess the possible mechanisms of the VD3 effects on the depression-like 
behavior in long-term OVX rats given with low dose of 17β-E2 subjected to CUMS.
2. Materials and methods
2.1 Animals
A total of 49 Wistar rats of 3 months age, female sex (weighing 200–220 g) were 
purchased in this work. Animals were divided into experimental groups with access 
to rat standard food and water ad libitum. The female rats were placed under a 12 
light-dark scheme (light was given between 07:00 and 19:00 h) and room tempera-
ture (23 ± 2°C). All behavioral procedures and CUMS model were performed in 
compliance with the National research council’s guide for the care and use of labora-
tory animals and approved by the Ethical committee for experimental studies of 
I.P. Pavlov Institute of Physiology (statement No.: 1095/1/25.06.2012). Stress model 
of depression was conducted with minimal pain for all groups of rats.
2.2 Ovariectomy
Three months before CUMS procedure, sham operation and long-term total 
ovariectomy with general anesthesia (ketamine 70 mg/kg and xylazine 10 mg/kg, 
i.p.) were performed. Long-term period (3 months) elimination of female gonadal 
hormones was chosen as experimental model of menopause in women [44, 45]. The 
removal of ovaries was carried out accordingly to our method as prescribed earlier 
[43]. After surgery or sham-operation (SHAM), the ovariectomized (OVX) females 
were placed in home cage with free access to food and water. During 12 weeks, 
sham-operated and OVX females had a recovery. Following 3 months of surgery, 
experimental rats were randomly distributed to the groups for the chronic stress 
procedure, except for SHAM non-stressed control rats.
2.3 CUMS model
Chronic unpredictable mild stress (CUMS) paradigm is a valid and significant 
animal model of depression induced by stress procedure. This behavioral model 
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of depression state is strongly verified by both preclinical and clinical studies [46]. 
CUMS was made as described previously [47, 48]. The procedure included the expo-
sure to different and unpredictable stress factors that are randomly changed during 
experimental days [49]. These manipulations are 24 h food deprivation, 24 h water 
deprivation, wet bedding overnight, titled cage overnight, unpredictable shocks 
(15 mA, one shocks/20s, 10 s duration, 20 min), 5 min swimming at cold water 
(4°C), tail hanging, 1 min, clip tail for 1 min, reversal of light/dark cycle [47, 48]. All 
stress triggers were performed individually and continuously. To prevent habitu-
ation and to ensure the unpredictability of the stressors, all stress manipulations 
randomly made accordingly to experimental scheme, repeated throughout the 4 
weeks of CUMS protocol. The control SHAM females were placed in a separate room 
without any contact with the stressed groups of animals. These rats were maintained 
as undisturbed animals that are subjected only routine cage cleaning for 4 weeks. 
The total scheme of whole experiment is indicated on Figure 1.
2.4 Drugs
17β-E2, fluoxetine hydrochloride and VD3 as cholecalciferol were provided from 
Sigma Chemical Co. (St. Louis, MO, USA). The solution of female estrogen was 
prepared using sterile sesame oil. Vitamin D3 was dissolved in 95% ethanol and then 
aliquoted and remained at −80°C. The solution of cholecalciferol for the injection 
into the experimental groups was diluted in sterile water, resulting in a solvent 
of VD3 containing 2% ethanol. Fluoxetine hydrochloride was dissolved in sterile 
physiological saline. All drugs were injected subcutaneously (0.1 ml/rat) for the 
4 weeks during the CUMS procedure – 30 min before the daily stressor action – and 
throughout the period of the behavioral tests. All behavioral measurements were 
made 60 min after the last drug administration.
2.5 Groups of animals
All animals were randomly assigned to the six experimental groups (n = 7 in each): 
non-CUMS SHAM rats treated with solvent (control), SHAM rats exposed to CUMS 
treated with solvent, long-term OVX rats exposed to CUMS given with solvent, fluox-
etine as positive control (10.0 mg/kg/day), 17β-E2 (0.5 μg/rat/day, s.c.) or VD3 (5.0 mg/
kg/day, s.c.) in a combination with low dose of 17β-E2. In our preliminary studies, there 
were no significant differences between SHAM/OVX rats treated with physiological 
Figure 1. 
Timeline of chronic treatment. Female Wistar rats were divided into 6 groups – non-CUMS SHAM rats treated 
with solvent (control), SHAM rats submitted to CUMS treated with solvent, long-term OVX rats exposed to 
CUMS given with solvent, fluoxetine as positive control (10.0 mg/kg/day), 17β-E2 (0.5 μg/rat/day, s.c.) or VD3 
(5.0 mg/kg/day, s.c.) in a combination with low dose of 17β-E2.
5
Vitamin D3 Modulates NF-kB/p65, 17β-Estradiol, and Vitamin D Receptors Expression…
DOI: http://dx.doi.org/10.5772/intechopen.89357
saline as solvent for fluoxetine and SHAM/OVX females treated with sterile water 
with 2% ethanol as solvent for VD3 or SHAM/OVX females treated with sesame oil as 
solvent for 17β-E2 in behavioral trials (data are not shown). Since, we did not found any 
differences between these experimental groups, the sesame oil as solvent for SHAM/
OVX females was used in the present work. The dose of VD3 and dose of 17β-E2 were 
based on our previous work on the behavioral effects of VD3 on depression-like behav-
ior of long-term OVX female rats submitted to CUMS [42, 43]. The dose of fluoxetine 
was utilized according to earlier studies demonstrating that the administration of 
fluoxetine decreases depressive-like behavior in rodents [42]. All drugs were injected 
subcutaneously (0.1 ml/rat) for the 4 weeks during the CUMS procedure – 30 min 
before the daily stressor action – and throughout the period of the behavioral tests. All 
behavioral measurements were made 60 min after the last drug administration.
2.6 Sucrose preference test
We performed SPT accordingly to our previous study [50, 51]. Before and after 
the initiation of the 4 weeks CUMS procedures, the experimental rats were sub-
jected to the sucrose preference test (SPT) [42, 51]. This test is set up as follows: fol-
lowing a training trial, the rats are subjected to a 24 h deprivation of food and water. 
On the next day, the rats have 1 hour access to one bottle with 200 ml of water and 
a similar amount of sucrose solution. The experimenter measures the percentage of 
the consumed sucrose solution and water volumes as a measure of sucrose prefer-
ence by calculating the value of the sucrose preference among all (sucrose plus 
water in mL) liquid consumption:
  %sucrose preference =  
sucrose consumption
   _________________________________   
sucrose consumption + water consumption
 × 100  (1)
2.7 Forced swimming test
For testing of modifications of depression-like behavior, all groups of rats were 
submitted to the standard forced swimming test (FST) as described in earlier works 
(FST) [42, 43]. The three cylinders (60 cm tall and diameter 20 cm) were filled with 
23–25°C water up to a 30-cm depth. On the first day, rats were pre-tested during 15 min 
in cylinders. Then, rats were dried with papers and placed at their home cages till the 
next day. On the second day (testing trial), OVX females with CUMS were examined 
into the apparatus for 5 min. The following parameters were registered: (1) immobility 
time (floating in the water with only movements necessary to keep the head above 
water); (2) swimming time (active swimming movements around glass cylinder); 
(3) climbing time (active movements with forepaws directed toward the walls). For 
recording of these values, a video camera was installed above the apparatus.
2.8 Open field test
The measurements of the behavioral activity in the OFT were carried out in a 
similar way to the method which has been published in a previous study [43]. The 
rats were set in the center square of the OFT and tested for 5 min. Motor activity 
and rearing and grooming behavior were recorded for 300 s in the OFT apparatus 
using a video camera, and equipment was cleaned in-between sessions.
2.9 Biochemical measurements
All rats underwent a narcosis after behavioral trials, and approximately 5 ml 
samples of blood were drawn from the animals to be centrifuged at 4000 g for 
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15 min at 4°C [43]. While doing so, the hippocampi of rats in the experimental 
group were dissected to be homogenized in cold lysis extraction buffer (0.2% 
sodium deoxycholate, 0.5% Triton X-100, 1% NP-40, 50 mM Tris-HCl pH 7.4, 
1 mM phenylmethylsulfonyl fluoride, 1 mM N-ethyl-maleimide, and 2.5 mM 
phenanthroline) [43]. After that, the hippocampal samples with the cold lysis 
buffer were sonicated for 15 s. Then, the hippocampi were centrifuged at 12,000 g 
for 15 min at 4°C. The Bradford method was used for the normalization of hippo-
campal supernatants to the total protein [52]. The serum samples and hippocampal 
protein normalized supernatants were stored at −80°C until the ELISA assays. The 
serum samples were used for the measurement of the 25-hydroxyvitamin D3 (25-
OH-VD3) and estradiol levels using a commercially available rat ELISA kits (Cusabio 
Biotech Co., Ltd., Wuhan, P.R. China) according to the manufacturer’s instructions. 
The sensitivity and detection range of the 25-OH-VD3 rat ELISA kits were 5.0 μg/l 
and 20–100 μg/l, respectively. The sensitivity and detection range of the estradiol 
rat ELISA kits were 4.0 pg/ml and 40–1500 pg/ml, respectively.
Hippocampal homogenates were used for the detection of the NF-kB/p65/p65, 
17β-E2/VD3 receptors levels by rat ELISA kits (Cusabio Biotech Co., Ltd., Wuhan, 
P.R. China) according to the manufacturer’s instructions. Briefly, 100 𝜇l of hip-
pocampal sample or standard was added to each well and incubated for 120 min 
at 37.0°C. Then, 100 𝜇l of anti-NF-kB/p65/p65, anti-17β-E2 receptor, and anti-VD3 
receptor antibodies were added to each different well and incubated for 60 min at 
37.0°C. After 3 times of washing, 100 𝜇l of HRP-avidin working solution was added 
to each well and incubated for 60 min at 37.0°C. Again, after 5 times of washing, 90 
𝜇l of tetramethylbenzidine solution was given to each different well and incubated 
for 15–30 min at 37.0°C. Then, 50 𝜇l of stop solution was added to each well to 
terminate the color reaction. The NF-kB/p65/p65, 17β-E2/VD3 receptors levels were 
measured using a MC Thermo Fisher Scientific reader (Thermo Fisher Scientific 
Inc., Finland) with an absorbance of 450 nm. The standard curve was used for the 
calculation of the relationship between the optical density and the NF-kB/p65/p65, 
17β-E2/VD3 receptors levels. The BDNF content is presented as pg/mg of tissue. 
The sensitivity and detection range of the NF-kB/p65 rat ELISA kit were 5.0 μg/
ml and 6.0–600 μg/ml, respectively. The sensitivity and detection range of the 
17β-E2 receptor rat ELISA kit was 0.39 pg/ml and 1.56–100 pg/ml, respectively. The 
sensitivity and detection range of the VD3 receptor rat ELISA kit was 5.8 pg/ml and 
23.5–1500 pg/ml, respectively. The assay exhibited no significant cross reactivity 
with other ligands. All samples were duplicated for the assay.
2.10 Western blots
Hippocampal tissues were homogenized in cold lysis buffer containing a protease 
inhibitor cocktail (Sigma-Aldrich, USA) for 1 h and centrifuged at 12,000 g at 4°C for 
20 min [42]. The protein content was evaluated by a Bio-Rad protein detector (Bio-
Rad, USA), and 100 μg of total protein from each sample was denatured with buffer 
(6.205 mM Tris-HCl, 10% glycerol, 2% SDS, 0.01% bromophenol blue, and 50 mM 
2ME) at 95°C for 5 min. The denatured proteins were separated on an SDS page 
(10% sodium dodecyl sulfate polyacrylamide gel) and forwarded to a nitrocellulose 
membrane (Amersham Biotech, USA). After that, the membranes were probed with 
anti-NF-kB/p65/p65, anti-17β-E2 receptor, anti-VD3 receptor (1:1000, Santa Cruz), 
and β-actin (1:1000; Sigma-Aldrich, USA) monoclonal antibodies for 2 h and sec-
ondary antirabbit antibodies (1:5000; Santa Cruz, USA) conjugated to horseradish 
peroxidase for 1 h. Bands were detected by 5-bromo-4-chloro-3-indolyl phosphate 
with a nitro blue tetrazolium kit (Abcam, China) as a chemiluminescent substrate. 
Signals were measured by an image analysis system (UVIdoc, Houston, TX, USA).
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2.11 Statistical analysis
All experimental data are expressed as the mean ± standard deviation of the 
mean. The treatment effects were determined with a one-way ANOVA followed by 
an LSD post hoc test using the Statistics Package for SPSS, version 16.0 (SPSS Inc., 
USA). A value of P < 0.05 was considered statistically significant.
3. Results
3.1  VD3 alters the body weight in the long-term OVX rats treated with 17β-E2 
exposed to CUMS
The body weights of long-term OVX rats subjected to CUMS and treated with 
17β-E2 in a combination with all investigated doses of VD3 are presented in Figure 2.
There was no difference in the initial body weight in all the experimental 
groups. Following 4 weeks, the body weight of SHAM rats with CUMS was 
significantly decreased compared to the control, non-CUMS SHAM group 
(Figure 2, F(1,34) = 72.66, P < 0.001). The body weight of long-term OVX 
rats with CUMS was significantly decreased compared to the non-CUMS/
CUMS SHAM groups (Figure 2, P < 0.001). Administration of 17β-E2 did not 
statistically enhance body weight of long-term OVX rats with CUMS compared 
to the non-CUMS control, CUMS OVX/SHAM groups (Figure 2, P > 0.001). 
However, there was a tendency to increase the body weight of long-term OVX 
Figure 2. 
VD3 corrects the body weight in the long-term OVX rats treated with 17β-E2 submitted to CUMS: (a) Prior 
to CUMS and (b) After CUMS. * – P < 0.05 versus the control group, # – P < 0.05 versus to the SHAM group 
with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the OVX group 
with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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rats with CUMS compared to the OVX rats plus CUMS given with solvent. 
Supplementation with VD3 (5.0 mg/kg) plus 17β-E2 significantly prevented the 
reduction of the body weight of long-term OVX rats with CUMS (P < 0.001) 
compared to the OVX plus solvent or 17β-E2/SHAM rats exposed to CUMS 
(Figure 2, P < 0.001). This effect of co-administration of VD3 (5.0 mg/kg) plus 
17β-E2 was similar to the effect of the reference drug fluoxetine (10.0 mg/kg) in 
long-term OVX rats with CUMS.
3.2  VD3 increases sucrose preference in the long-term OVX rats treated with 
17β-E2 exposed to CUMS
Before the CUMS protocol, there was no significant difference among the 
experimental groups in the SPT (Figure 3). Following 28 days of the CUMS 
trials, the SHAM rats exhibited a decrease in sucrose preference when compared 
to the control non-CUMS SHAM group (P < 0.05). The sucrose preference in 
long-term OVX rats was significantly reduced compared to the non-CUMS/
CUMS SHAM rats (Figure 3, F(1,34) = 56.14, P < 0.05). Low dose of 17β-E2 
increased sucrose preference in long-term OVX rats with CUMS compared to the 
OVX group with CUMS plus solvent (Figure 3, P > 0.05). Treatment with VD3 at 
dose of 5.0 mg/kg plus 17β-E2, as well as fluoxetine, markedly increased sucrose 
Figure 3. 
VD3 increases sucrose preference in the long-term OVX rats treated with 17β-E2 submitted to CUMS:  
(a) Prior to CUMS and (b) After CUMS. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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consumption in the long-term OVX rats exposed to CUMS when compared to 
the OVX plus solvent or 17β-E2/SHAM rats submitted to the CUMS (Figure 3, 
P < 0.05).
3.3  VD3 decreases depression-like behavior in the forced swimming test of  
long-term OVX rats treated with 17β-E2 exposed to CUMS
CUMS produced a significant increase of the immobility time and decrease of 
swimming time in the long-term OVX compared to the non-CUMS/CUMS SHAM 
rats (Figure 4, F(1,34) = 52.84, F(1,76) = 68.89, F(1,76) = 26.12, respectively, 
Figure 4. 
VD3 decreased depression-like behavior in the forced swimming test of long-term OVX rats treated with 17β-E2 
submitted to CUMS: (a) immobility time, sec, (b) swimming time, and (c) climbing time, sec. * – P < 0.05 
versus the control group, # – P < 0.05 versus to the SHAM group with CUMS, $ – P < 0.05 versus to the OVX 
group with CUMS, and $$ – P < 0.05 versus to the OVX group with CUMS treated with 17β-E2. The data are 
presented as mean ± SD; n = 7 in each group.
Vitamin D Deficiency
10
P < 0.05). VD3 (5.0 mg/kg), as well as fluoxetine treatment, significantly reduced 
the immobility time and increased the swimming time in the long-term OVX 
treated with 17β-E2 compared to the OVX plus solvent or 17β-E2/SHAM with CUMS 
groups (Figure 4, P < 0.05).
3.4  VD3 changes the behavior in the open field test of long-term OVX rats 
treated with 17β-E2 exposed to CUMS
Following 28 days of CUMS protocol, there were no statistically significant 
differences for grooming activities between all the experimental groups of animals 
in the OFT (Figure 5, F(1,34) = 0.82, P > 0.05). The long-term OVX rats with CUMS 
Figure 5. 
VD3 alters the behavior in the open field test of long-term OVX rats treated with 17β-E2 submitted to CUMS. 
(a) Crossing, (b) rearing, and (c) grooming. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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showed a decreased number of rearings and crossings when they were compared 
to the non-CUMS/CUMS SHAM groups (Figure 5, F(1,34) = 14.14, P < 0.05). 
Administration of fluoxetine, 17β-E2, as well as treatment with VD3 significantly 
elevated the number of rearings and crossings in the long-term OVX rats with CUMS 
compared to the OVX/SHAM rats with CUMS plus solvent (Figure 5).
3.5  VD3 alters serum estradiol and VD3 levels in long-term OVX rats treated 
with 17β-E2 exposed to CUMS
The ELISA assay revealed decreased estradiol and VD3 concentrations in the 
long-term OVX rats with CUMS compared to the non-CUMS/CUMS SHAM 
groups (Figure 6, F(1,34) = 78.56, F(1,34) = 56.12, F(1,34) = 22.21, respectively, 
P < 0.05). Low dose of 17β-E2 induced increase of estradiol levels in the serum 
blood to some extent in the long-term OVX rats with CUMS, however, it was 
not statistically significant (P > 0.05). The co-administration of VD3 with 
17β-E2 significantly increased estradiol and VD3 concentrations in the long-
term OVX rats with CUMS compared to the OVX plus solvent or 17β-E2/SHAM 
with CUMS rats (Figure 6, P < 0.05). Fluoxetine did not change the serum 
Figure 6. 
VD3 alters serum estradiol and VD3 levels in long-term OVX rats treated with 17β-E2 submitted to CUMS.  
(a) estradiol, pg/ml and (b) 25-OH-VD3, μg/ml. * – P < 0.05 versus the control group, # – P < 0.05 versus to the 
SHAM group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the 
OVX group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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estradiol and VD3 levels in the long-term OVX rats exposed to CUMS (Figure 6, 
P > 0.05).
3.6  VD3 modulates hippocampal NF-kB/p65/p65 and 17β-E2/VD3 receptors 
levels in long-term OVX rats treated with 17β-E2 exposed to CUMS
CUMS significantly increased NF-kB/p65/p65 levels and decreased 17β-E2/VD3 
receptors concentrations in the hippocampus of SHAM rats compared to the non-
CUMS control (Figure 7, P < 0.05). CUMS produced a increase of hippocampal 
Figure 7. 
VD3 modulates hippocampal NF-kB/p65 and 17β-E2/VD3 receptors levels in long-term OVX rats treated with 
17β-E2 submitted to CUMS tested by ELISA. (a) NF-kB/p65/p65, μg/ml, (b) 17β-E2 receptor, pg/ml, and (c) 
VD3 receptor, pg/ml. * – P < 0.05 versus the control group, # – P < 0.05 versus to the SHAM group with CUMS, 
$ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the OVX group with CUMS 
treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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NF-kB/p65/p65 and decrease of 17β-E2/VD3 receptors levels in the long-term OVX rats 
compared to the non-CUMS/CUMS SHAM rats (Figure 7, F(1,34) = 28.44, P < 0.05).
Fluoxetine (10.0 mg/kg) decreased NF-kB/p65/p65 levels in the hippocampus of 
long-term OVX rats treated to CUMS compared to the OVX plus solvent/SHAM rats 
with CUMS (Figure 7, P < 0.05). Moreover, VD3 plus 17β-E2 reversed 17β-E2/VD3 
receptors levels and reduced NF-kB/p65 levels in the hippocampus of the long-term 
OVX rats compared to OVX plus solvent or 17β-E2/SHAM rats with CUMS (Figure 7, 
P < 0.05). Fluoxetine failed to modify 17β-E2/VD3 receptors levels in the long-term 
OVX rats exposed to CUMS (Figure 7, P > 0.05).
Western blotting analysis revealed that NF-kB/p65 protein levels in the hippocam-
pus of SHAM rats submitted to CUMS were higher compared to non-CUMS control 
Figure 8. 
VD3 modulates hippocampal NF-kB/p65 and 17β-E2/VD3 receptors expressions in long-term OVX rats with 
17β-E2 submitted to CUMS detected with western blotting treated. 1 – control SHAM, 2 – SHAM + CUMS + 
solvent, 3 – OVX + CUMS + solvent, 4 – OVX rats + CUMS + fluoxetine, 5 – OVX rats + CUMS + 17β-E2, and 
6 – OVX rats + CUMS + VD3 + 17β-E2. * – P < 0.05 versus the control group, # – P < 0.05 versus to the SHAM 
group with CUMS, $ – P < 0.05 versus to the OVX group with CUMS, and $$ – P < 0.05 versus to the OVX 
group with CUMS treated with 17β-E2. The data are presented as mean ± SD; n = 7 in each group.
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females (Figure 8, P < 0.05). NF-kB/p65 levels were increased in the hippocampus 
of long-term OVX rats with CUMS compared to the non-CUMS/CUMS SHAM 
rats (Figure 8, F(1,34) = 34.45, F(1,34) = 16.38, respectively, P < 0.05). Fluoxetine 
(10.0 mg/kg) resulted in significant reduced levels of hippocampal NF-kB/p65 protein 
expression in long-term OVX with CUMS compared to the OVX plus solvent/SHAM 
rats with CUMS (Figure 8, P < 0.05). Co-treatment with VD3 and 17β-E2 decreased 
NF-kB/p65 protein levels and increased 17β-E2/VD3 receptors protein expression in 
the hippocampus of the long-term OVX rats compared to OVX plus solvent or 17β-E2/
SHAM rats with CUMS (Figure 8, P < 0.05). Fluoxetine did not alter 17β-E2/VD3 
protein expression in the long-term OVX rats exposed to CUMS (Figure 8, P > 0.05).
4. Discussion
The present preclinical study analyzed the antidepressant-like effects of VD3 
(5.0 mg/kg, s.c.) in long-term adult OVX female rats given with low dose of 17β-E2 
subjected to the CUMS. A CUMS paradigm is a well-known experimental paradigm 
that has documented to consider as standard pathophysiological impairments in 
mood state linked to a clinical depressive disorders in humans [47–49]. In the pres-
ent work, the implications of NF-kB/p65 signaling pathway, as well as the 17β-E2/
VD3 receptors, in the mechanisms of VD3 activity in depression were tested regard-
ing to the affective-related condition of long-term adult OVX rats treated with low 
dose of 17β-E2 exposed to CUMS.
The results of this study showed that in the adult long-term OVX rats undergo-
ing CUMS, there were marked anhedonia-/depression-like behaviors, as assessed by 
SPT and LDT, respectively.
Moreover, long-term OVX rats exposed to CUMS exhibited decreased loco-
motor and rearing activities in the OFT. The ELISA assay clearly demonstrated 
lower estradiol and VD3 concentrations in adult long-term OVX rats subjected to 
CUMS. In addition, the increased NF-kB/p65 concentration/protein expression and 
decreased 17β-E2/VD3 receptors levels were found in the hippocampus of long-term 
OVX rats exposed to CUMS.
Administration of 17β-E2 failed to completely restore behavioral and biochemi-
cal parameters in the long-term OVX rats exposed to CUMS. Fluoxetine decreased 
anhedonia-like and depression-like states and decreased NF-kB/p65 levels in the 
hippocampus of the long-term OVX female rats exposed to CUMS. Data of litera-
ture have demonstrated that fluoxetine corrected depression-like profile of OVX 
rats in stress depression model [53]. The results of the study indicate that CUMS 
provokes marked behavioral, neurochemical, neurohormonal, and neuroinflamma-
tion alterations in adult OVX rats with long-lasting estrogens decline. Our data are 
in agreement with our recent data and other findings, which indicated that long-
term estrogen deprivation in female rodents subjected to a CUMS procedure results 
in a profound affective-like profile [54].
The most important findings of the present study is linked to the antidepressant-
like effects of VD3 in the long-term adult OVX rats treated with low dose of 17β-E2 
under conditions of CUMS. VD3 given with a dose of 5.0 mg/kg reversed anhe-
donia-like and depression-like states in the SPT/LDT paradigms in the long-term 
OVX rats treated with 17β-E2 subjected to CUMS, which was similar to the effects 
of the fluoxetine treatment. Moreover, the VD3 application reversed the behavioral 
impairments observed in the OFT in the long-term OVX rats supplemented with 
17β-E2 subjected to CUMS. Biochemical assays found that VD3 increased the serum 
VD3 and estradiol levels, as well decreased the hippocampal NF-kB/p65 content in 
the long-term OVX rats treated with 17β-E2 exposed to CUMS. Additionally, VD3 
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increased 17β-E2/VD3 receptors levels in the hippocampus of long-term OVX rats 
treated with 17β-E2 subjected to CUMS. Western blot analysis revealed that VD3 
reduced NF-kB/p65 and increased 17β-E2/VD3 protein expression in the hip-
pocampus of long-term OVX rats treated with 17β-E2 subjected to CUMS. These 
data suggest that VD3 attenuates the CUMS-produced behavioral impairments and 
normalized the serum VD3 and estradiol levels, as well NF-kB/p65 and 17β-E2/VD3 
production in the hippocampus of long-term OVX rats.
Inflammation is now recognized to be the one of the key components of affec-
tive-related development, with the NF-κB involved in both the early and late stages 
of the inflammatory processing [33, 41, 55]. NF-κB is the main transcriptional 
factor which controls the expression of various genes implicated in multiple cell 
functions and is triggered by different types of extracellular stimuli stimulated neu-
roinflammation [33, 34]. Deterioration of NF-κB signaling in the brain negatively 
influence on neuroplasticity and neuromorphology, as well as cognitive functions. 
However, NF-κB overstimulation is deleterious, and this detrimental effect can be 
reversed suppressing NF-κB signaling. That is why, NF-κB signaling is fundamental 
for normal brain function [36–39, 55]. The inhibition of neuroinflammation may 
be critical for the antidepressant action of VD3 that was noted in our study. The 
increased pro-inflammatory cytokines have been found repeatedly in both animals 
and depressed patients [37–39]. Clinical studies indicate that inhibition of neuroin-
flammation by nonsteroidal antiinflammatory drugs can attenuate depression-like 
behaviors in depressed rodents and humans [36–39]. The inhibitory effect of VD3 
on CUMS-induced increase in pro-inflammatory cytokines in the hippocampus 
of the long-term OVX rats is strongly in accordance with the neuroinflammation 
hypothesis of depression [39]. A better comprehension of NFκB-dependent mecha-
nisms in antidepressant action of VD3 needs further studies.
Based on our findings, it can be assumed that VD3 in the present study is impli-
cated in the modulation of NF-κB signaling in long-term OVX rats with CUMS. On 
the other hand, VD3 normalized 17β-E2/VD3 receptors levels in the hippocampus of 
long-term OVX rats treated with 17β-E2 subjected to CUMS. Such complex effects 
of VD3 on neuroinflammation and 17β-E2/VD3 receptors might promote a greater 
effect of combination of VD3 plus 17β-E2 than application only 17β-E2. This is the 
first study to show the action of VD3 in the behavioral and neuroinflammation and 
biochemical consequences of a CUMS in adult long-term OVX rats treated with low 
dose of 17β-E2. The inhibition of NF-kB/p65 activity by VD3 treatment is a promis-
ing fact of study for treatment of neuroinflammatory diseases that are associated 
with low levels of VD3. These results suggest an anti-inflammatory role for VD3, 
which may be one of the fundamental components of its activity.
Thus, the possible mechanism of VD3 action might be explained by the stimula-
tion of 17β-E2/VD3 receptors identified in the different brain structures involved 
in mood control [13–15]. The possible mechanisms of such action of VD3 in the 
long-term OVX rats can be connected with cross-talk protein-protein interactions. 
Moreover, VD alters the neuroinflammation response via NF-kB/p65 signaling at 
the affective-related state, thereby improving depression state [39, 55]. Low VD 
levels appear in the majority of postmenopausal women [52, 56, 57]. Therefore, VD 
supplementation may be very useful for treatment of mood disorders in postmeno-
pausal women with a low level of VD and supplemented with MHT. However, the 
exact role of VD supplementation in the prevention and treatment of mood disor-
ders associated with menopausal consequences has not been completely identified.
In conclusion, the present study supports evidence for repeated administra-
tion of VD3 in a chronic unpredictable stress model having an anti-anhedonia-like 
and antidepressant-like effects in long-term OVX adult rats treated with low dose 
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implications of NF-kB/p65 and 17β-E2/VD3 production modulation in the antide-
pressant-like activity of VD3. Further studies should however explore the precise 
mechanism of VD3 action, due to the necessity of an improvement of therapies 
focusing on mood-repair in females with long-lasting estrogen deficiency.
5. Conclusions
This study demonstrated that VD3-induced antianhedonic- and antidepressant-
like effects in the adult female rats following long-lasting estrogens decline treated 
with low dose of 17β-E2 submitted to CUMS. Treatment with VD3 modulates 
NF-kB/p65 concentration/protein expression and 17β-E2/VD3 receptors levels in 
the hippocampus of long-term OVX rats exposed to CUMS treated with low dose of 
17β-E2. Our study yields new knowledge into the mechanisms by which VD3 affects 
to alleviate anhedonia- and depressive-like behaviors in female rodents with long-
term estrogen deficiency in stress model of depression.
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